Supporting this mechanism, preclinical studies in MET-amplified NSCLC and gastric cancer have demonstrated that high extracellular HGF concentrations markedly impair the efficacy of MET-TKIs (Pennacchietti et al., 2014). Here, HGF is linked to non-small cell lung carcinoma.